Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.038955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Arnaud S Girard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval Québec QC Canada. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Lipoprotein(a), Aortic Valve, Calcinosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Lp(a) (lipoprotein(a)) is an independent risk factor for calcific aortic valve stenosis (CAVS). Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events is unknown. The aim of this study is to determine whether higher Lp(a) levels are associated with valvular and cardiovascular outcomes in patients with CAVS. Methods and Results We identified 1962 patients from the UK Biobank with an electronic health record or self‐reported CAVS diagnosis but who did not previously undergo aortic valve replacement (AVR) and had a minimal follow‐up time of 2.5 years. Cox proportional hazard regression was used to evaluate the effect of Lp(a) on AVR, AVR or cardiac death, and valvular or cardiovascular events (AVR, cardiac death, myocardial infarction, stroke, heart failure, or coronary artery bypass grafting). The maximal follow‐up time was set to 5 years. During the follow‐up, 198 patients underwent AVR, 260 had AVR or cardiac death, and 435 had at least 1 valvular or cardiovascular event. Patients with Lp(a) levels ≥125 versus
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval Québec QC Canada.
- Department of Medicine, Faculty of Medicine Université Laval Québec QC Canada.
- Eli Lilly Indianapolis IN USA.
- Department of Surgery, Faculty of Medicine Université Laval Québec QC Canada.
- Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine Université Laval Québec QC Canada.
ORCID-Profile: Arnaud S Girard, Audrey Paulin, Hasanga D Manikpurage, Marie-Annick Clavel, Philippe Pibarot, John H Krege, Patrick Mathieu, Sébastien Thériault, Benoit J Arsenault
Zitieren
APA
Girard, A. S., Paulin, A., Manikpurage, H. D., Lajeunesse, E., Clavel, M. A., Pibarot, P., Krege, J. H., Mathieu, P., Thériault, S., & Arsenault, B. J. (2025). Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.038955
Vancouver
Girard AS, Paulin A, Manikpurage HD, Lajeunesse E, Clavel MA, Pibarot P, et al. Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.038955
BibTeX
@article{Girard2025,
author = {Girard, Arnaud S and Paulin, Audrey and Manikpurage, Hasanga D and Lajeunesse, Emma and Clavel, Marie-Annick and Pibarot, Philippe and Krege, John H and Mathieu, Patrick and Thériault, Sébastien and Arsenault, Benoit J},
title = {Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.038955}
}
EUVIMED